Skip to main content
PolicySpeak
← All files
TPU

Takeda Pharmaceuticals USA

Company · Ireland

not in the EU Transparency RegisterThis organization files on consultations without a register number, so its record here is built from its filings alone. Register facts (staff, costs, accreditations) are not available for it.

2
positions filed
in the 665 files tracked
1
legislative file
of 665 tracked
2
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.

Track Takeda in PolicySpeak: request access →

Follow Takeda Pharmaceuticals USA

An email when this organization files on a consultation we publish.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Work at Takeda Pharmaceuticals USA? so we know who speaks for it.

Their record over time

Takeda Pharmaceuticals USA filed 2 positions between 6 Oct 2025 and 31 Jul 2026, across 1 of the 665 legislative files tracked here, attaching a full position paper 2 times.

2025 · 1 filed2026 · 1 filed

What they argued

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 31 Jul 2026PDFsource

Takeda Pharmaceuticals welcomes the opportunity to provide comments on the proposed changes to the medical device and in vitro diagnostic regulatory frameworks. Overall, we support measures that promote a more proportionate, risk-based, and harmonised regulatory system while maintaining robust standards for patient safety and device performance.

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 6 Oct 2025PDFsource

As both a medicinal product and medical device manufacturer, Takeda Pharmaceuticals welcomes the opportunity to provide evidence on specific challenges the MDR and IVDR have presented to pharmaceutical companies within the EU. Please find attached detailed information on the key challenges Takeda has encountered due to MDR and IVDR along with some proposed solutions to address these issues in the future.

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Put Takeda Pharmaceuticals USA next to another organization. Same files, same register facts, side by side. Compare →

Is this your organization?

Everything on this page comes from Takeda Pharmaceuticals USA’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.